ReviewGenes2020
Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Review in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- MCM2 germline variants predispose to familial papillary thyroid carcinoma due to genomic instability caused by MCM complex disruption.Oncogene · 2026Article
- Differences in the aggressiveness of familial versus sporadic non-medullary thyroid cancer: An unresolved controversy.Archives of endocrinology and metabolism · 2026Article
- Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.Molecular & cellular oncology · 2026Article
- Approach to the Pediatric Patient With Thyroid Nodules.The Journal of clinical endocrinology and metabolism · 2025Review
- Global landscape of early-onset thyroid cancer: current burden, temporal trend and future projections on the basis of GLOBOCAN 2022.Journal of global health · 2025Article
- Thyroid Cancer in Childhood Cancer Survivors: Demographic, Clinical, Germline Genetic Characteristics, Treatment, and Outcome.Journal of clinical medicine · 2025Article
- State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.Biomedicines · 2024Review
- Clinically Relevant Germline Variants in Children With Nonmedullary Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2024Article
- Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.Cancers · 2023Article
- Cancer Predisposition Syndromes and Thyroid Cancer: Keys for a Short Two-Way Street.Biomedicines · 2023Review
- Epidemiology of Thyroid Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Squamous Differentiation in the Thyroid: Metaplasia, Neoplasia, or Bystander?International journal of surgical pathology · 2022Article
- Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.Frontiers in endocrinology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is the most frequent endocrine malignancy with the majority of cases derived from thyroid follicular cells and caused by sporadic mutations. However, when at least two or more first degree relatives present thyroid cancer, it is classified as familial non-medullary thyroid cancer (FNMTC) that may comprise 3-9% of all thyroid cancer. In this context, 5% of FNMTC are related to hereditary syndromes such as Cowden and Werner Syndromes, displaying specific genetic predisposition factors. On the other hand, the other 95% of cases are classified as non-syndromic FNMTC. Over the last 20 years, several candidate genes emerged in different studies of families worldwide. Nevertheless, the identification of a prevalent polymorphism or germinative mutation has not progressed in FNMTC. In this work, an overview of genetic alteration related to syndromic and non-syndromic FNMTC is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.